Leukocyte telomere length in patients with myotonic dystrophy type I: a pilot study. Voet NB, van der Kooi EL, van Engelen BG, Geurts AC.Ĭochrane Database Syst Rev. Strength training and aerobic exercise training for muscle disease. Pagola-Lorz I, Vicente E, Ibáñez B, Torné L, Elizalde-Beiras I, Garcia-Solaesa V, García F, Delfrade J, Jericó I. doi: 10.1097/MD.0000000000017582.Įpidemiological study and genetic characterization of inherited muscle diseases in a northern Spanish region. Portaro S, Naro A, Leo A, Cimino V, Balletta T, Buda A, Accorinti M, Calabrò RS. Overground exoskeletons may boost neuroplasticity in myotonic dystrophy type 1 rehabilitation: A case report. Review.ĭiabetes, Metformin, and Cancer Risk in Myotonic Dystrophy Type I.Īlsaggaf R, Pfeiffer RM, Wang Y, St George DMM, Zhan M, Wagner KR, Amr S, Greene MH, Gadalla SM. Johnson NE, Aldana EZ, Angeard N, Ashizawa T, Berggren KN, Marini-Bettolo C, Duong T, Ekström AB, Sansone V, Tian C, Hellerstein L, Campbell C. Ĭonsensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1. Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models.īargiela A, Sabater-Arcis M, Espinosa-Espinosa J, Zulaica M, Lopez de Munain A, Artero R. Targeting myotonic dystrophy by preimplantation genetic diagnosis-karyomapping. Recovery in the Myogenic Program of Congenital Myotonic Dystrophy Myoblasts after Excision of the Expanded (CTG) n Repeat.Īndré LM, van Cruchten RTP, Willemse M, Bezstarosti K, Demmers JAA, van Agtmaal EL, Wansink DG, Wieringa B. Shields RK, Lee J, Buelow A, Petrie M, Dudley-Javoroski S, Cross S, Gutmann L, Nopoulos PC. Myotonic dystrophy type 1 alters muscle twitch properties, spinal reflexes, and perturbation-induced trans-cortical reflexes. Spaziani M, Semeraro A, Bucci E, Rossi F, Garibaldi M, Papassifachis MA, Pozza C, Anzuini A, Lenzi A, Antonini G, Radicioni AF. Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study. MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy. Review.īioactive Aliphatic Polycarbonates Carrying Guanidinium Functions: An Innovative Approach for Myotonic Dystrophy Type 1 Therapy.īaroni A, Neaga I, Delbosc N, Wells M, Verdy L, Ansseau E, Vanden Eynde JJ, Belayew A, Bodoki E, Oprean R, Hambye S, Blankert B.ĪCS Omega. Swinnen B, Robberecht W, Van Den Bosch L.ĮMBO J.
RNA toxicity in non-coding repeat expansion disorders.
0 kommentar(er)
